The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- Ordinary Profit Ratio Averages 18.2% for 27 Listed Firms
June 25, 2001
- OTC NEWS IN BRIEF
June 18, 2001
- Tsumura to Jointly Study Cultivation of Crude Drugs with Chinese Firm
June 18, 2001
- Pharmacists Regarded as 4th Most Reliable: Survey
June 18, 2001
- Discussions Must Be Restarted from 10% R-zone: Mr Matsutani
June 18, 2001
- Kahma: Net Loss of \670 Million
June 18, 2001
- CS Yakuhin to Reduce Ratio of Expenses to Gross Revenue to 8%
June 18, 2001
- NIC Corp: Sales of Drug Dispensing Business Up 28.8%
June 18, 2001
- BUSINESS NEWS IN BRIEF
June 18, 2001
- Kraft: Record-high Operating, Ordinary Profits
June 18, 2001
- 10 Reported Products Including Diprivan Inj. Added to NHI Price List
June 18, 2001
- Kyowa Hakko Starts PII for KW-7158 in Europe
June 18, 2001
- 14 Active Ingredients Included in NHI Price List
June 18, 2001
- Takeda Discovers Metastasis Suppressor Peptide Ligand
June 18, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -1-
June 18, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIE -1-
June 18, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -2-
June 18, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
June 18, 2001
- Patient-Oriented Healthcare Discussed: JPMA Seminar
June 18, 2001
- REGULATORY NEWS IN BRIEF
June 18, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…